New study seeks best dose of alectinib for ALK-Positive lung cancer patients
NCT ID NCT05713006
First seen Apr 22, 2026 · Last updated Apr 29, 2026 · Updated 3 times
Summary
This study tests three different doses of the drug alectinib in 45 Mexican patients with advanced ALK-positive non-small cell lung cancer. The goal is to find the safest and most effective dose by measuring drug levels in the blood and tumor response. Participants will take alectinib twice daily, starting at a low dose and increasing, and continue treatment as long as it helps.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE IIIB are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Thoracic Oncology Unit and Personalized Medicine Laboratory, Instituto Nacional de Cancerología
RECRUITINGMexico City, Mexico City, 14080, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.